218301-62-3

Usage

Uses

Used in Pharmaceutical Industry:
4-(3-Fluoro-4-nitrophenyl)Morpholine is used as a synthetic intermediate for the development of new drugs. Its unique chemical properties, including the presence of fluorine and nitro groups, make it a promising candidate for the creation of pharmaceutical compounds with novel therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical sector, 4-(3-Fluoro-4-nitrophenyl)Morpholine serves as a key intermediate in the synthesis of agrochemicals. Its potential applications in this industry include the development of new pesticides, herbicides, and other agricultural chemicals that can improve crop protection and yield.
Used in Organic Synthesis:
4-(3-Fluoro-4-nitrophenyl)Morpholine is utilized as a versatile building block in organic synthesis. Its unique structure and chemical properties allow for a wide range of synthetic applications, enabling the creation of various biologically active compounds with potential uses in different industries.

Upstream product

• 110-91-8 morpholine 
• 446-35-5 2,4-Difluoronitrobenzene 
• 369-34-6 3,4-difluoronitrobenzene 

Downstream Products

• 1313809-83-4 C₂₂H₂₁F₂N₃O₂S 
• 1313809-84-5 C₂₂H₂₁F₂N₃O₂S 
• 1313809-85-6 C₂₂H₂₀F₃N₃O₂S 
• 1313809-86-7 C₂₃H₂₁FN₄O₂S 
• 1313809-87-8 C₂₂H₂₁FN₄O₄S 
• 1313809-88-9 C₂₅H₂₈FN₃O₂S 
• 1313809-89-0 C₂₃H₂₄FN₃O₃S 
• 1313809-90-3 C₂₂H₂₁FN₄O₄S 
• 1313809-91-4 C₂₂H₂₁BrFN₃O₂S 
• 1313809-92-5 C₂₃H₂₄FN₃O₄S 
• 1313809-93-6 C₂₅H₂₈FN₃O₅S 
• 1313809-94-7 C₂₄H₂₃FN₄O₂S 
• 1357481-41-4 1-ethyl-3-(2-fluoro-4-(morpholin-4-yl)phenyl)thiourea 
• 1313809-78-7 3-ethyl-2-(2-fluoro-4-(morpholin-4-yl)phenylimino)thiazolidin-4-one 

Relevant academic research and scientific papers

SYK INHIBITOR AND USE METHOD THEREFOR

Provided are a Syk inhibitor and a use method therefor, and in particular, disclosed are quinolinone represented by formula (I) or quinazoline derivatives or pharmaceutically acceptable salts thereof, a preparation method, a pharmaceutical composition, and uses in preparing a medicament for treatment of Syk receptor related diseases.

Synthesis and Structural Investigation of Some Electron-Rich Nitroaromatics

2,4-Difluoro-, 2,4,6-Trifluoro-, and 2,3,4,6,tetrafluoronitrobenzenes undergo nucleophilic aromatic substitution, once, twice, and three times with a variety of amine substituents with a high degree of regiochemical control to provide a range of electron-

Continuous Synthesis and Purification by Coupling a Multistep Flow Reaction with Centrifugal Partition Chromatography

Continuous-flow multistep synthesis is combined with quasi-continuous final-product purification to produce pure products from crude reaction mixtures. In the nucleophilic aromatic substitution of 2,4-difluoronitrobenzene with morpholine followed by a het

Continuous synthesis and purification by direct coupling of a flow reactor with simulated moving-bed chromatography

Continuous synthesis meets continuous purification to produce pure products from crude reaction mixtures. In the nucleophilic aromatic substitution of 2,4-difluoronitrobenzene with morpholine the desired monosubstituted product can be continuously separated from the byproducts in a purity of over 99 % by coupling a flow reactor to a simulated moving bed (SMB) chromatography module (see scheme). Copyright

Synthesis of 5-benzylidene-3-(3-fluoro-4-yl-morpholin-4-yl-phenylimino)- thiazolidin-4-one derivatives catalyzed by [BmIm]OH and their anti-microbial activity

A series of novel 5-benzylidene-3-(3-fluoro-4-yl-morpholin-4-yl- phenylimino)thiazolidin-4-one derivatives were synthesized using [bmIm]OH as a catalyst and were tested for their antibacterial and antifungal activities. These compounds showed moderate in

NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS

The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula (I) or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is N or NH and D may be C(=NH)NH2, which are useful as inhibitors of factor Xa.

Discovery of 1-(3′-aminobenzisoxazol-5′-yl)-3-trifluoromethyl- N-[2-fluoro-4-[(2′-dimethylaminomethyl)imidazol-1-yl]phenyl] -1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor

Modification of a series of pyrazole factor Xa inhibitors to incorporate an aminobenzisoxazole as the P1 ligand resulted in compounds with improved selectivity for factor Xa relative to trypsin and plasma kallikrein. Further optimization of the P4 moiety led to compounds with enhanced permeability and reduced protein binding. The SAR and pharmacokinetic profile of this series of compounds is described herein. These efforts culminated in 1-(3′-aminobenzisoxazol-5′-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2′-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide (11d), a potent, selective, and orally bioavailable inhibitor of factor Xa. On the basis of its excellent in vitro potency and selectivity profile, high free fraction in human plasma, good oral bioavailability, and in vivo efficacy in antithrombotic models, the HCl salt of this compound was selected for clinical development as razaxaban (DPC 906, BMS-561389).

NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS

The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula (I) or pharmaceutically acceptable salt forms thereof, wherein rings D-E represent guanidine mimics, which are useful as inhibitors of factor Xa.

[Bmim]PF6 and BF4 ionic liquids as novel and recyclable reaction media for aromatic amination

Activated aryl halides undergo smooth nucleophilic substitution reactions with secondary amines in 1-butyl-3-methylimidazolium hexafluorophosphate ([bmim]PF6) or 1-butyl-3-methylimidazolium tetrafluoroborate ([bmim]BF4) ionic liquids (ILs) at room temperature to afford the corresponding arylamines in excellent yields under mild and neutral conditions.

Guanidine mimics as factor Xa inhibitors

The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula I: or pharmaceutically acceptable salt forms thereof, wherein rings D—E represent guanidine mimics, which are useful as inhibitors of factor Xa.